Sunitinib facilitates the activation and recruitment of therapeutic anti-tumor immunity in concert with specific vaccination. - Wikidata - wikimedia - TriplyDB

Sunitinib facilitates the activation and recruitment of therapeutic anti-tumor immunity in concert with specific vaccination.

Sunitinib facilitates the activation and recruitment of therapeutic anti-tumor immunity in concert with specific vaccination.

http://www.wikidata.org/entity/Q35033957

about

Combining radiotherapy with sunitinib: lessons (to be) learned Hampering immune suppressors: therapeutic targeting of myeloid-derived suppressor cells in cancer Ways to enhance lymphocyte trafficking into tumors and fitness of tumor infiltrating lymphocytes Control of the immune response by pro-angiogenic factors Signal transducer and activator of transcription 3 in myeloid-derived suppressor cells: an opportunity for cancer therapy Myeloid derived suppressor cells-An overview of combat strategies to increase immunotherapy efficacy Inhibition of Fatty Acid Oxidation Modulates Immunosuppressive Functions of Myeloid-Derived Suppressor Cells and Enhances Cancer Therapies Modification of the tumor microenvironment as a novel target of renal cell carcinoma therapeutics Reduced immunosuppressive properties of axitinib in comparison with other tyrosine kinase inhibitors.Myeloid derived suppressor cells - a new therapeutic target in the treatment of cancer.The immunocytokine NHS-IL12 as a potential cancer therapeutic Intratumorally injected pro-inflammatory allogeneic dendritic cells as immune enhancers: a first-in-human study in unfavourable risk patients with metastatic renal cell carcinoma.Circulating Type-1 Anti-Tumor CD4(+) T Cells are Preferentially Pro-Apoptotic in Cancer Patients.Immune consequences of decreasing tumor vasculature with antiangiogenic tyrosine kinase inhibitors in combination with therapeutic vaccines.Melan-A/MART-1 immunity in a EWS-ATF1 translocated clear cell sarcoma patient treated with sunitinib: a case report MDSC as a mechanism of tumor escape from sunitinib mediated anti-angiogenic therapy.Sunitinib indirectly enhanced anti-tumor cytotoxicity of cytokine-induced killer cells and CD3⁺CD56⁺ subset through the co-culturing dendritic cells.The combination of a novel immunomodulator with a regulatory T cell suppressing antibody (DTA-1) regress advanced stage B16F10 solid tumor by repolarizing tumor associated macrophages in situ.Chronic inflammation and immunologic-based constraints in malignant disease.Chemokines, costimulatory molecules and fusion proteins for the immunotherapy of solid tumors.Consequence of dose scheduling of sunitinib on host immune response elements and vaccine combination therapy Immune consequences of tyrosine kinase inhibitors that synergize with cancer immunotherapy Combined Tbet and IL12 gene therapy elicits and recruits superior antitumor immunity in vivo.Combined vaccine+axitinib therapy yields superior antitumor efficacy in a murine melanoma model.A rationally designed combined treatment with an alphavirus-based cancer vaccine, sunitinib and low-dose tumor irradiation completely blocks tumor development.Inhibition of the angiopoietin/Tie2 axis induces immunogenic modulation, which sensitizes human tumor cells to immune attack.Myeloid-derived suppressor cells adhere to physiologic STAT3- vs STAT5-dependent hematopoietic programming, establishing diverse tumor-mediated mechanisms of immunologic escape.Deficiency of Kruppel-like factor KLF4 in mammary tumor cells inhibits tumor growth and pulmonary metastasis and is accompanied by compromised recruitment of myeloid-derived suppressor cells DLK1: a novel target for immunotherapeutic remodeling of the tumor blood vasculature.Immune-checkpoint blockade and active immunotherapy for glioma.Fallen angels or risen apes? A tale of the intricate complexities of imbalanced immune responses in the pathogenesis and progression of immune-mediated and viral cancers.Combination of sunitinib with anti-tumor vaccination inhibits T cell priming and requires careful scheduling to achieve productive immunotherapy.Control of the adaptive immune response by tumor vasculature.Dasatinib promotes the expansion of a therapeutically superior T-cell repertoire in response to dendritic cell vaccination against melanoma.Role of myeloid-derived suppressor cells in tumor immunotherapy.Combining immunotherapy and targeted therapies in cancer treatment.Oncolytic virotherapy for renal cell carcinoma: a novel treatment paradigm?Strategies for enhancing vaccine-induced CTL antitumor immune responses.Modulation of immunity by antiangiogenic molecules in cancer.The potential role of sunitinib targeting melanomas.

P2860

Q26800587-EBE0945E-F7A4-46A1-9316-7BB955708AB6 Q26863418-5429FFFB-ECCA-4273-B05A-56EDA58DBDF3 Q26991991-2A893477-B88A-428B-B501-6C2F596FB33B Q27004733-12DCFEE4-A923-4C19-9C97-51E3B2022241 Q28080262-3EF6216D-072C-45F2-BA86-CF83DB34C268 Q28082461-AA163E51-CBD5-45D7-AFE7-512DF5FF6604 Q28393381-977CD231-F17B-47B9-B3E8-5F4FEA0EFF4B Q28393614-9AF3D4E4-C58C-4D6D-BCFC-4FC9346B19B1 Q30317831-52D56D0C-2037-444B-996C-F4D2A4B74380 Q33606107-ED691622-44B7-4968-80D2-0A263221BCEB Q33688398-1B969EDC-0B53-4A93-BB1D-B9BEF02E2C5D Q33814322-9E78E412-FFC2-4C15-AE5A-E398403A9FF7 Q34259974-E5433DEE-DF43-4177-8783-D6EF37552939 Q34458617-A3F32392-B7CA-44B8-8CB1-E4A4AD6799DE Q34669336-15FB4B50-D3AC-4A58-8926-F35596DED349 Q35028389-0C587C1A-4469-4AE5-AB47-BAD2AD5BC937 Q35043102-6E89838B-21CC-4D9B-BBEC-9F174CAD9643 Q35507095-871A5179-27AC-4AC6-A25F-1009E018694C Q35575974-CA4E516B-6E49-4476-B108-B6537D8206D7 Q35580479-1CFE76C8-1B61-4D89-9E68-32C1C22221F1 Q35597086-54503945-C181-4B73-A970-42BAC7AD6527 Q35634179-7D25E169-6F85-47B3-91E7-C8E1FA78BBAC Q35802152-AB4C6AB9-A9D4-4A22-8AA6-862D42B0D373 Q35923178-73ADCB72-425A-48A5-8A4D-C9A496A60046 Q36107975-804032AB-E29C-446B-A60F-73D24C6D1FD6 Q36286833-411489E6-0840-4FA5-924B-D523CAC7DBDB Q37066106-CE856FAD-427B-4D53-8D82-56D8F1A40F0E Q37228480-9AF22260-5514-4043-8FE8-C45D463AF09B Q37254877-5F3DB4B7-FEA0-4E52-B8C2-FC368A679853 Q37420586-6CD8C86A-1C72-4EBA-BB53-68B1324B20EB Q37620568-5A66EDFF-6C3D-4A59-9821-1645208AC68F Q37625756-D26896DE-4356-473F-B632-317F0A852FAE Q37683575-B1D15C7C-9A23-4ADC-ABF5-1DEF33E4D361 Q37698857-61222A32-B544-4D68-9B4D-AC2F3BA10736 Q37965750-C2EFBB5E-3E0C-49DB-AC13-E53FFC33910B Q37995939-B4BB57E1-E058-4445-8C4C-A01A1AABBED1 Q38008023-6A03777C-D547-47E4-AF11-286D3A25ACBF Q38055143-79E60F0A-E809-4371-8032-AC199E49CBC2 Q38074154-335DF8EA-EA17-4F5B-B40C-DBD5B44988F8 Q38139560-21B85D9A-9EF5-43CD-AA90-B9F2D1545972

P2860

Sunitinib facilitates the activation and recruitment of therapeutic anti-tumor immunity in concert with specific vaccination.

http://www.wikidata.org/entity/Q35033957

description

2011 nî lūn-bûn

@nan

2011 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Sunitinib facilitates the acti ...... ert with specific vaccination.

@ast

Sunitinib facilitates the acti ...... ert with specific vaccination.

@en

type

label

Sunitinib facilitates the acti ...... ert with specific vaccination.

@ast

Sunitinib facilitates the acti ...... ert with specific vaccination.

@en

prefLabel

Sunitinib facilitates the acti ...... ert with specific vaccination.

@ast

Sunitinib facilitates the acti ...... ert with specific vaccination.

@en

P1433

Q35033957-7FE19A7D-6CAD-4755-AB47-66A3EB565518

P1476

Q35033957-5B25B68E-1170-4A07-9D43-014BC12390B6

P2093

Q35033957-0A0C92EC-D1F3-48E6-8888-EBE18E8FB74E

Q35033957-27B937E5-96DE-4E58-81C3-152E290B2281

Q35033957-3A52E32B-D3EE-42A2-BB7B-8A17571B849B

Q35033957-3BF9CB3C-29D9-437E-8D95-61A86E01D87F

Q35033957-628BCA8E-C424-48EC-B647-B3B78034C533

Q35033957-80973948-1B6D-4FF7-B902-C689CD7169EA

Q35033957-82998C81-EAB3-4360-B54A-6E0CD91DEAC0

Q35033957-D01CBBE5-2138-4952-A6A2-33BFFD4DDDF4

Q35033957-D0DC3458-2840-4D02-BC7B-F83ED94B5B16

Q35033957-E1871425-5D0A-4810-AEBB-50DE87475EB3

P2860

Q35033957-047994AC-0A0B-421A-BFCC-35F4674A8312

Q35033957-04908D1E-B5B5-4420-A733-98DF51143465

Q35033957-0A510AFC-CFEC-4E1D-AFFD-1D2BDF674FF7

Q35033957-0BAA2F66-6193-4D0A-8490-48CE11655FF0

Q35033957-0C9C0877-1AA6-47FA-BCA9-CFD4DADC071C

Q35033957-12905E8E-2A5F-488A-8E24-0044563F522F

Q35033957-1B5753DD-D0A5-4FF5-BED1-114FC61D5D86

Q35033957-1BD4121E-3548-4E36-9668-5F3A705757BB

Q35033957-242F1505-67D8-46C2-A603-9BF47C8B414B

Q35033957-343D9B23-F89F-4F92-9A16-6A62D46DF786

P304

Q35033957-1558FDDD-0D78-4B20-9334-4ABB17995DAC

P31

Q35033957-4F224D05-A851-4944-A877-58DB0C27D29D

P356

Q35033957-EE599729-8802-46D6-A32C-728C1CDCDD10

P433

Q35033957-3FEFA70C-8367-4778-88E1-88B41AB2E419

P478

Q35033957-96F079E7-5BC1-4918-9148-805763D2A131

P577

Q35033957-2781CB57-9044-4B9B-86BD-F2224DAD6A15

P5875

Q35033957-4D62B03B-D73F-4ACC-AB74-893C33E17AD6

P698

Q35033957-9765CEE2-C861-4C43-94BA-5A4EBDA0C483

P932

Q35033957-71404D34-8912-4DF3-8EF8-D90C36309E2C

P356

P1433

International Journal of Cancer

P1476

Sunitinib facilitates the acti ...... ert with specific vaccination.

@en

P2093

Anamika Bose

http://www.w3.org/2001/XMLSchema#string

Brian I Rini

http://www.w3.org/2001/XMLSchema#string

James H Finke

http://www.w3.org/2001/XMLSchema#string

Jennifer L Taylor

http://www.w3.org/2001/XMLSchema#string

Jennifer S Ko

http://www.w3.org/2001/XMLSchema#string

Jorge A Garcia

http://www.w3.org/2001/XMLSchema#string

Peter A Cohen

http://www.w3.org/2001/XMLSchema#string

Sean Alber

http://www.w3.org/2001/XMLSchema#string

Simon C Watkins

http://www.w3.org/2001/XMLSchema#string

Walter J Storkus

http://www.w3.org/2001/XMLSchema#string

P2860

Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 protein

Selectivity and therapeutic inhibition of kinases: to be or not to be?

Proinflammatory S100 proteins regulate the accumulation of myeloid-derived suppressor cells

The ligands of CXC chemokine receptor 3, I-TAC, Mig, and IP10, are natural antagonists for CCR3

Stroma-derived factor (SDF-1/CXCL12) and human tumor pathogenesis

Role of angiogenesis in tumor growth and metastasis

Altering regulatory T cell function in cancer immunotherapy: a novel means to boost the efficacy of cancer vaccines.

Resistance to antiangiogenic therapy is directed by vascular phenotype, vessel stabilization, and maturation in malignant melanoma.

Overview of rationale and clinical trials with signal transduction inhibitors in lung cancer.

Sunitinib in patients with metastatic renal cell carcinoma.

P304

2158-2170

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/IJC.25863

http://www.w3.org/2001/XMLSchema#string

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

129

http://www.w3.org/2001/XMLSchema#string

P577

2011-05-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

229657358

http://www.w3.org/2001/XMLSchema#string

P698

21170961

http://www.w3.org/2001/XMLSchema#string

P932

3110980

http://www.w3.org/2001/XMLSchema#string